Nevala Terhi, Biancari Fausto, Manninen Hannu, Aho Pekka-Sakari, Matsi Pekka, Mäkinen Kimmo, Roth Wolf-Dieter, Ylönen Kari, Lepäntalo Mauri, Perälä Jukka
Department of Radiology, Oulu University Hospital, Oulu, Finland.
J Vasc Interv Radiol. 2009 Apr;20(4):448-54. doi: 10.1016/j.jvir.2008.12.410. Epub 2009 Feb 11.
To assess the midterm results of endovascular repair of abdominal aneurysm (AAA) with a Zenith stent-graft.
Between January 2001 and December 2005, a Zenith stent-graft was employed for endovascular repair of an infrarenal AAA in 206 patients. The mean patient age (+/-standard deviation) was 73.2 years +/- 7.3. Bifurcated grafts were used in 196 patients (96.1%), aortouni-iliac grafts were used in seven patients (3.4%), and a tubular graft was used in one patient (0.5%). The mean follow-up period was 2.4 years +/- 1.7.
The 30-day mortality rate was 2.9%. The overall survival rates at 1-, 3-, and 5-year follow-up were 93.3%, 78.7%, and 64.5%, respectively. None of the patients died of AAA rupture. The primary and assisted technical success rates 1 week after endovascular aneurysm repair were 82.0% and 90.3%. The primary clinical success rates at the 1-, 3-, and 5-year follow-up were 90.6%, 85.6%, and 83.5%. Twenty-seven patients (13.1%) underwent a secondary intervention during the study period.
An 83% rate of freedom from repeat vascular intervention over a period of 5 years as well as an absence of structural failures or aneurysm ruptures demonstrates that a Zenith stent-graft is associated with good midterm results.
评估使用Zenith覆膜支架进行腹主动脉瘤（AAA）血管腔内修复的中期结果。
2001年1月至2005年12月期间，206例患者采用Zenith覆膜支架进行肾下腹主动脉瘤的血管腔内修复。患者平均年龄（±标准差）为73.2岁±7.3岁。196例患者（96.1%）使用分叉型移植物，7例患者（3.4%）使用主动脉单髂动脉移植物，1例患者（0.5%）使用管状移植物。平均随访期为2.4年±1.7年。
30天死亡率为2.9%。1年、3年和5年随访时的总生存率分别为93.3%、78.7%和64.5%。无患者死于腹主动脉瘤破裂。血管腔内动脉瘤修复术后1周的初次和辅助技术成功率分别为82.0%和90.3%。1年、3年和5年随访时的初次临床成功率分别为90.6%、85.6%和83.5%。27例患者（13.1%）在研究期间接受了二次干预。
5年内83%的患者无需重复血管干预，且无结构故障或动脉瘤破裂，表明Zenith覆膜支架具有良好的中期结果。
